Cargando…

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaflard, Pauline, Paoletti, Xavier, Servois, Vincent, Tresca, Patricia, Pons-Tostivint, Elvire, Sablin, Marie-Paule, Ricci, Francesco, Loirat, Delphine, Hescot, Ségolène, Torossian, Nouritza, Bello Roufai, Diana, Kamal, Maud, Borcoman, Edith, Le Tourneau, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602606/ https://www.ncbi.nlm.nih.gov/pubmed/34562258 http://dx.doi.org/10.1007/s40268-021-00362-3

Ejemplares similares

Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial
por: Dupain, Célia, et al.
Publicado: (2020)

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Gougis, Paul, et al.
Publicado: (2019)

Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie
por: Basse, Clémence, et al.
Publicado: (2018)

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial
por: Basse, Clémence, et al.
Publicado: (2018)

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
por: Le Tourneau, C, et al.
Publicado: (2012)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
por: Borcoman, Edith, et al.
Publicado: (2017)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma
por: Pons-Tostivint, Elvire
Publicado: (2023)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Petak, Istvan, et al.
Publicado: (2021)

Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
por: Denis, Marc G., et al.
Publicado: (2023)

Metastasis of Ciliary Body Melanoma to the Contralateral Eye: A Case Report and Review of Uveal Melanoma Literature
por: Torossian, Nouritza M., et al.
Publicado: (2015)

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
por: Le Tourneau, Christophe, et al.
Publicado: (2020)

RAIDS atlas of significant genetic and protein biomarkers in cervical cancer
por: Scholl, Suzy, et al.
Publicado: (2023)

Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial
por: Desportes, Emilie, et al.
Publicado: (2016)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

Thyroid cells seeding along the transaxillary approach after robot-assisted transaxillary surgery (RATS) for a benign node
por: Louvel, Rémy, et al.
Publicado: (2022)

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells
por: Congras, Annabelle, et al.
Publicado: (2018)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2018)

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
por: Mathiot, Laurent, et al.
Publicado: (2022)

A fatal case associated with Catabacter hongkongensis bacteremia in lung cancer patient: A case report
por: Mandin, Valentin, et al.
Publicado: (2022)

Treatment time interval in breast cancer: A population‐based study on the impact of type and number of cancer centres attended
por: Martinez, Amalia, et al.
Publicado: (2022)

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03
por: Fayette, Jerome, et al.
Publicado: (2017)

Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency
por: Bello-Roufaï, Mahajoub, et al.
Publicado: (2007)

Dyslipidemia causes overestimation of plasma mitotane measurements
por: Paci, Angelo, et al.
Publicado: (2016)

Reply to Ivica Ratosa et al. Comment on: “Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study”
por: Pons-Tostivint, E., et al.
Publicado: (2020)

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
por: de Guillebon, E., et al.
Publicado: (2021)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas
por: Sablin, Marie-Paule, et al.
Publicado: (2016)

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
por: de Moura, Alexandre, et al.
Publicado: (2023)

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis
por: Moreau Bachelard, Camille, et al.
Publicado: (2021)

Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients
por: Neuzillet, Cindy, et al.
Publicado: (2021)

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
por: Le Tourneau, Christophe, et al.
Publicado: (2023)

Première vague COVID-19 : expérience d’un centre de lutte contre le cancer
por: Frelaut, Maxime, et al.
Publicado: (2021)

Maladaptive Daydreaming, Dissociation, and the Dissociative Disorders
por: Ross, Colin A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_138p14e6s71616086m3uebu7rn